Enclomiphene Citrate Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management

What enclomiphene citrate is, and what it is not

Enclomiphene citrate is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). It is chemically related to, but not identical with, the racemic clomiphene citrate marketed in the United States as Clomid, which is FDA-approved for inducing ovulation in women. Enclomiphene as a standalone product does not currently hold FDA approval for any indication in the United States; when it is prescribed for men with low testosterone due to secondary hypogonadism, that use is off-label and the product is typically obtained through a compounding pharmacy rather than as an FDA-approved drug. Readers should not assume the regulatory status or quality-control standards that apply to an FDA-approved product apply equally to a compounded one, and should confirm current status with their pharmacist, since compounding rules and product availability can change.

Mechanistically, enclomiphene blocks estrogen receptors in the hypothalamus, which reduces negative feedback and increases pulsatile release of gonadotropin-releasing hormone (GnRH). This raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates testicular testosterone production. Small controlled studies in men with secondary hypogonadism have reported that enclomiphene at doses in the 12.5 to 25 mg daily range raised testosterone into the normal range while preserving sperm parameters, in contrast to topical testosterone replacement, which can suppress sperm production. The specific trial commonly cited for this finding could not be independently verified for this revision, and readers relying on it for clinical decisions should confirm the citation against the primary literature before treating the figures as settled.

Because the drug's central effect is dose-dependent, higher intake produces stronger hypothalamic estrogen receptor blockade and a larger downstream hormonal swing. That is the pharmacologic reason dose matters for overdose risk, even though receptor saturation provides some ceiling effect against runaway stimulation.

The core answer, and its boundary

No published case series or regulatory safety communication reviewed for this article documents a fatal or clearly life-threatening overdose of enclomiphene or racemic clomiphene citrate in any population. Reported adverse effects at supratherapeutic exposure are gastrointestinal (nausea, vomiting) and ophthalmologic (blurred vision, scotomata, flashes, floaters), consistent with the dose-related visual warning carried on the clomiphene citrate FDA label. This pattern supports a wide apparent margin of safety for isolated excess doses in adults, but it does not establish safety for sustained supratherapeutic dosing, pediatric ingestion, or use in people with pre-existing liver or eye disease, and a formal overdose or toxicology database analysis specific to enclomiphene has not been identified.

What counts as an overdose here

Any intake above the prescribed amount is technically an overdose, but the clinical significance varies enormously by amount and duration.

A single accidental double dose (for example, taking a second 25 mg capsule by mistake) brings total intake for that day to 50 mg. That is still within the range of doses that have been used clinically for clomiphene citrate in fertility and hypogonadism protocols, so an isolated event of this size in an otherwise healthy adult is unlikely to cause more than transient symptoms. Sustained supratherapeutic dosing over days to weeks is a different situation: it can drive meaningful estradiol suppression and a higher chance of visual or mood symptoms, and it deserves clinician contact even without dramatic symptoms.

The FDA label for clomiphene citrate (Clomid) permits regimens up to 100 mg daily for five days in the approved female indication, and describes visual symptoms as dose-related in nature. That labeling applies to racemic clomiphene in women, not to compounded enclomiphene in men, but it is the closest FDA-anchored dosing and safety reference available and is a reasonable point of comparison when judging how far outside a normal range an accidental dose falls. (FDA label, Clomid, 2012)

Expected symptoms after an accidental excess dose

Gastrointestinal symptoms. Nausea, vomiting, and abdominal discomfort are the most commonly reported acute symptoms after excess SERM intake. These are typically self-limited and resolve within about a day.

Visual disturbances. The clomiphene citrate label warns of blurred vision, spots or flashes of light (scotomata and photopsia), and states that visual symptoms tend to increase with higher total dose or longer duration of therapy and generally resolve after the drug is stopped, though the label also notes that prolongation can occur in rare cases. Readers who want the exact label wording should consult the linked FDA document directly rather than rely on a paraphrase, since a long verbatim quotation could not be independently re-verified for this revision.

Vasomotor symptoms. Hot flashes and flushing can occur from acute estrogen receptor antagonism in thermoregulatory centers. Uncomfortable, not dangerous.

Hormonal effects with sustained overdosing. Days to weeks of supratherapeutic dosing can push testosterone well above baseline and suppress estradiol. Low estradiol in men can produce joint discomfort, mood changes, irritability, and reduced libido, a pattern that overlaps with what is sometimes seen with aromatase inhibitor overtreatment. Precise numeric thresholds vary by lab and patient, and any specific number quoted to you as a "cutoff" for a symptom should be treated as a rough clinical guide rather than a fixed rule.

What has not been reported. Cardiac arrhythmia, seizure, respiratory depression, and loss of consciousness are not part of the documented clomiphene-class SERM overdose picture in the sources reviewed. That absence of evidence should be read as reassuring but not as proof of absolute safety, since dedicated overdose toxicology studies on enclomiphene specifically are sparse.

Step-by-step management of a known or suspected excess dose

There is no specific antidote. Management is supportive and symptom-directed.

1. Contact Poison Control or emergency services. Call 1-800-222-1222 for any intake meaningfully above the prescribed dose. Go to the emergency department directly if there are visual symptoms, altered mental status, or severe or persistent vomiting.
2. Stop dosing until symptoms resolve and a clinician has reassessed the situation. Enclomiphene's elimination half-life has been reported in small pharmacokinetic work as roughly 10 hours, which would predict that plasma levels fall substantially within one to two days of stopping, though this figure should be confirmed against the primary pharmacokinetic literature rather than treated as an exact clinical guarantee.
3. Do not attempt home decontamination measures on your own. Activated charcoal can be appropriate for large recent ingestions in a monitored setting, but timing and dosing should be directed by Poison Control or emergency staff, not self-administered. Induced vomiting is not recommended for any overdose scenario under current toxicology guidance.
4. Get a formal eye exam if there are any visual symptoms. Blurred vision, scotomata, or light sensitivity after excess intake warrants ophthalmologic evaluation, both to document the finding and to rule out other causes.
5. Consider hormone labs for sustained or large overdoses. Total testosterone, estradiol, LH, FSH, and a basic metabolic panel can help characterize the degree of HPG axis disruption and inform how soon a rechallenge with the prescribed dose might be reasonable. Specific numeric cutoffs for "markedly elevated" or "suppressed" values should come from the treating clinician and the reference ranges of the testing lab.
6. Supportive care for symptoms: IV fluids for dehydration from vomiting, antiemetics as directed by a clinician, and observation until symptoms settle.

Decision framework: what to do after an accidental excess dose

This framework is a general decision aid, not individualized medical advice, and does not replace a call to Poison Control or your prescriber.

The unifying principle: the size of a single accidental extra dose matters less than (1) whether visual symptoms appear, (2) whether the excess dosing is a one-time event or sustained over days, and (3) whether the person has a modifier such as liver disease, concurrent aromatase inhibitor use, or is a child. Any one of those three shifts the response from "monitor at home" toward "get evaluated."

Enclomiphene versus racemic clomiphene: why the isomer distinction is relevant to overdose duration

Racemic clomiphene citrate (Clomid) is a mixture of the enclomiphene (trans) isomer and the zuclomiphene (cis) isomer. Zuclomiphene is a weak estrogen agonist that has been described in the pharmacology literature as having a substantially longer half-life than enclomiphene, on the order of weeks rather than hours, though exact figures vary between sources and should be confirmed against a primary pharmacokinetic study before being treated as precise. Because compounded enclomiphene products are intended to contain the trans-isomer without the long-acting zuclomiphene component, an accidental excess dose of pure enclomiphene would be expected, on pharmacologic grounds, to clear faster and produce a shorter window of symptoms than an equivalent overdose of racemic clomiphene. This is a plausible and mechanistically reasonable inference rather than a directly demonstrated clinical outcome, since dedicated comparative overdose data are limited.

For a patient who has taken excess compounded enclomiphene rather than racemic clomiphene, this pharmacokinetic reasoning is a source of reassurance about duration, but it is not a substitute for confirming what the compounded product actually contains, since compounded formulations can vary by pharmacy.

Risk factors that may worsen outcomes after excess dosing

• Concurrent aromatase inhibitor use. Combining excess enclomiphene with an aromatase inhibitor such as anastrozole can produce additive estrogen suppression, with a higher chance of joint discomfort, mood disturbance, and, with chronic suppression, bone health concerns.
• Pre-existing visual or retinal disease. A lower threshold for SERM-associated visual symptoms is plausible in patients with prior retinal disease, cataracts, or optic neuropathy, though this has not been quantified in the sources reviewed.
• Hepatic impairment. Enclomiphene undergoes hepatic metabolism; reduced liver clearance could prolong exposure after an overdose. The clomiphene citrate label advises caution in patients with liver disease.
• Polypharmacy affecting the hypothalamic-pituitary-gonadal axis. Concurrent testosterone, hCG, or GnRH analogue use can make the hormonal response to an excess SERM dose less predictable.

Preventing accidental excess doses

Compounded enclomiphene capsules are dispensed in varying strengths across pharmacies (for example 6.25 mg, 12.5 mg, 25 mg, and 50 mg), which creates real potential for dose confusion when a patient switches pharmacies or refills from a different source. Practical steps: confirm capsule strength every time you fill a new prescription, use a pill organizer, set a consistent daily reminder, and never adjust your own dose without talking to your prescriber first.

If you realize you took an extra dose, skip the next scheduled dose rather than trying to "average out" the total by taking a smaller amount later. A single extra dose at a typical prescribed strength (12.5 to 25 mg) is unlikely to cause symptoms in an otherwise healthy adult, but it is still worth mentioning to your prescriber.

When to seek emergency care versus monitor at home

Home monitoring is reasonable for a single extra dose in a healthy adult with no visual symptoms: skip the next dose and watch for visual changes over the following day.

Seek emergency evaluation if the ingested amount clearly exceeds 100 mg in one episode, if any visual symptoms develop, if vomiting is severe or persistent, if a child or adolescent has taken any amount, or if the person has liver disease or is on medications that also affect the hypothalamic-pituitary-gonadal axis. When in doubt, calling Poison Control (1-800-222-1222) costs little and gives a same-call answer from a clinician trained in overdose triage.

What is established, what is plausible, and what is not established

Established: Clomiphene-class SERMs carry a labeled, dose-related risk of visual side effects; racemic clomiphene citrate is FDA-approved only for female ovulation induction; standalone enclomiphene citrate is not FDA-approved and male use is off-label, typically via compounding.

Plausible but not rigorously demonstrated for enclomiphene specifically: that a single accidental excess dose in a healthy adult is very unlikely to cause more than transient symptoms; that pure enclomiphene overdose resolves faster than racemic clomiphene overdose because it lacks the long-acting zuclomiphene isomer; specific numeric half-life and incidence figures cited in secondary sources, which should be checked against primary pharmacokinetic and pharmacovigilance literature before being relied on for a clinical decision.

Not established: any human lethal dose threshold for enclomiphene or clomiphene citrate; the true population incidence of overdose-related visual toxicity outside of therapeutic-dose safety data; long-term safety of enclomiphene overdose events beyond the observation periods described in available studies.

Long-term considerations after an overdose event

A single accidental excess dose typically does not require a change in the long-term treatment plan. Skip the next dose, resume the prescribed regimen, and tell your prescriber at your next visit.

Sustained supratherapeutic dosing over multiple days may warrant a short washout period before restarting, guided by your prescriber, along with hormone labs (estradiol, total testosterone, LH, FSH) at intervals your clinician selects. If estradiol suppression is unexpectedly severe or prolonged, it is reasonable to verify with the compounding pharmacy exactly what isomer composition the dispensed product contains, since a product mislabeled or compounded as racemic clomiphene rather than pure enclomiphene would explain a longer recovery.

Bone density evaluation is a reasonable consideration only after prolonged, marked estradiol suppression, since estrogen plays a documented role in bone maintenance in men; this should be a clinician-directed decision based on lab trends rather than a routine step after every overdose event.

No organ damage, cancer risk, or irreversible toxicity from a single acute excess dose has been documented in the sources reviewed for this article, which is consistent with a wide apparent therapeutic index. That statement describes the absence of reported harm in available literature, not proof that no such risk exists.

References

• U.S. Food and Drug Administration. Clomid (clomiphene citrate) prescribing information, 2012 label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016131s026lbl.pdf
• American Association of Poison Control Centers: 1-800-222-1222 (general public poison exposure hotline).

Reported figures such as pharmacokinetic values, incidence rates, and guideline statements vary between studies and have not been independently confirmed here. Readers should verify these details against current primary sources before making clinical decisions.